CD4 and neoplasm: In the CONFRONT phase I–II clinical trial, the combination of low dose cyclophosphamide and avelumab (anti-PD-1 mAb) was also shown to suppress the immunosuppressive effect of CD4+CD25+Foxp3+ Treg cells, which was accompanied by improved tumor-free survival in patients with metastatic head and neck cancer [68].